Cancer Genetics, Inc. (NASDAQ:CGIX) reported Q2 2017 earnings this Afternoon, coming in at ($0.16) per share, missing Wall Street’s estimates of ($0.15) per Share. Revenue for the quarter came in at $6.60 million missing the streets estimates of $7.97 million
Analyst Coverage For Cancer Genetics, Inc. (NASDAQ:CGIX)
These are 1 Hold Rating, 3 Buy Ratings .
The current consensus rating for Cancer Genetics, Inc. (NASDAQ:CGIX) is Buy (Score: 2.75) with a consensus target price of $6.00 , a potential (53.85% upside)Recent Insider Trading for Cancer Genetics, Inc. (NASDAQ:CGIX)
- On 6/12/2017 John Pappajohn, Director, bought 100,000 with an average share price of $3.75 per share and the total transaction amounting to $375,000.00.
- On 5/25/2017 Igor Gitelman, Insider, bought 937 with an average share price of $3.95 per share and the total transaction amounting to $3,701.15.
- On 5/23/2017 Igor Gitelman, Insider, sold 937 with an average share price of $4.02 per share and the total transaction amounting to $3,766.74.
- On 5/16/2017 Geoffrey E Harris, Director, bought 2,500 with an average share price of $3.75 per share and the total transaction amounting to $9,375.00.
- On 12/14/2016 Geoffrey E Harris, Director, bought 2,500 with an average share price of $1.50 per share and the total transaction amounting to $3,750.00.
- On 11/28/2016 John Pappajohn, Director, bought 100,000 with an average share price of $1.45 per share and the total transaction amounting to $145,000.00.
Recent Trading for Cancer Genetics, Inc. (NASDAQ:CGIX) Shares of Cancer Genetics, Inc. closed the previous trading session at 3.90 up +0.25 6.85% with 298,009 shares trading hands.